Information on Nanobiotix Capital

On October 20, 2026, Nanobiotix published its monthly statement regarding its share capital and associated voting rights. The company, listed on both Euronext Paris and Nasdaq, reported a total of 50,967,610 shares comprising its share capital as of September 30, 2026.

In terms of voting rights, the theoretical total, which includes all shares with voting rights, amounts to 54,729,543. The number of exercisable voting rights, exempting shares without voting rights, is 54,707,425. These figures are essential for monitoring participation thresholds.

Nanobiotix continues to develop innovative therapeutic solutions in the field of biotechnology. The company has subsidiaries in the United States and remains active on several research platforms focused on oncology and other biomedical applications.